Keywords: Gilead Sciences, 2009 results, Antivirals, Tamiflu
Antiviral franchise boosts Gilead's 4th-qtr income 43% to $802.2 million
Article | 27 January 2010
US biopharmaceutical company Gilead Sciences pleased investors yesterday, reporting a massive 43% rise in fourth-quarter 2009 net income to $802.2 million, fueled by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
